Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil Mesylate +/- Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT06105554Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belumosudil in multiple myeloma (MM) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events. Started Jan 2024; status: recruiting.
02
Drugs
belumosudil
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06105554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105554.